Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9491210.26442/2075-1753_19.12.20-24ArticlesСтатьиResearch ArticleGeneral principles and guidelines for the management and treatment of patients with gout on the basis of updated European recommendationsОбщие принципы и основные рекомендации по ведению и лечению пациентов с подагрой по материалам обновленных европейских рекомендацийTsurkoV. VЦуркоВладимир Викторович

д-р мед. наук, проф. каф. гематологии и гериатрии ИПО, проф. каф. факультетской терапии лечебного фак-та

GromovaM. AГромоваМаргарита Александровна

канд. мед. наук, ассистент каф. факультетской терапии лечебного фак-та

margarita-gromov@mail.ruI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationФГАОУ ВО «Первый МГМУ им. И.М.Сеченова», ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian FederationФГБОУ ВО «РНИМУ им. Н.И.Пирогова»N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation151220171912VOL 19, NO12 (2017)ТОМ 19, №12 (2017)202428122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94912

In 2016, updated European general principles and guidelines for managing patients with gout are published. The emphasis is on pharmacological/non-pharmacological methods of treatment and on urasnizhayuschee therapy in patients with impaired renal function. For the first time in Russia, along with allopurinol, a drug with a uracminating effect is recommended - febuxostat. The purpose of this review is to inform doctors about the mandatory achievement of a target uric acid level in the treatment of gout with hyperuricemia.

В 2016 г. опубликованы обновленные европейские общие принципы и основные рекомендации по ведению пациентов с подагрой. Акцент делается на фармакологические/нефармакологические методы лечения и на уратснижающую терапию у пациентов с нарушением функции почек. Впервые в России наряду с аллопуринолом рекомендуется препарат с уратснижающим эффектом - фебуксостат. Цель данного обзора - донести до врачей возможность обязательного достижения целевого уровня мочевой кислоты при лечении подагры с гиперурикемией.

gouthyperuricemiarecommendationstreatmentfebuxostatподаграгиперурикемиярекомендациилечениефебуксостатHootman J.M, Helmick C.G. Projections of US prevalence of arthritis and associated activity limitations. Arthr Rheum 2006; 54: 226-9.Насонова В.А., Барскова В.Г. Ранние диагностика и лечение подагры - научно обоснованное требование улучшения трудового и жизненного прогноза больных. Научно-практическая ревматология. 2004; 1: 5-7.Geiderman J.M. An elderly woman with a warm, painful finger. West J Med 2000; 172 (1): 51-2.Richette P, Doherty M, Pascual E et al. Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2016; Jul 25. PII: annrheumdis-2016-209707. DOI: 10.1136/annrheumdis-2016-209707Simkin P.A, Campbell P.M, Larson E.B. Brief report: Gout in Heberden’s nodes. Arthr Rheum 1983; 26: 97-104. DOI: 10.1016/j.berh.2015.04.024Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann Rheum Dis 2013; 72: 826-30.Choi J.W, Ford E.S, Gao X. et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109-16.Zhang Y, Neogi T, Chen C. et al. Cherry consumption and decreased risk of recurrent gout attacks. Arthritis Rheum 2012; 64: 4004-11.Dalbeth N, Ames R, Gamble G.D. et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial. Ann Rheum Dis 2012; 71: 929-34.Chen J.H, Wen C.P, Wu S.B. et al. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Ann Rheum Dis 2015; 74: 2034-42.Terkeltaub R.A, Furst D.E, Bennett K. et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010; 62: 1060-8.Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig 2014; 34: 845-55.Terkeltaub R.A, Furst D.E, Digiacinto J.L. et al. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum 2011; 63: 2226-37.Van Durme C.M, Wechalekar M.D., Buchbinder R. et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120.Rainer T.H, Cheng C.H, Janssens H.J. et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016; 164: 464-71.Janssens H.J, Janssen M, van de Lisdonk E.H. et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomized equivalence trial. Lancet 2008; 371: 1854-60.Wechalekar M.D, Vinik O, Schlesinger N. et al. Intra-articularglucocorticoids for acute gout. Cochrane Database Syst Rev 2013; 4: CD009920.Schlesinger N, Alten R.E, Bardin T. et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839-48.Ghosh P, Cho M, Rawat G. et al. Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res (Hoboken) 2013; 65: 1381-4.Finkelstein Y, Aks S.E, Hutson J.R. et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila) 2010; 48: 407-14.Becker M.A, MacDonald P.A, Hunt B.J. et al. Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy. Nucleosides Nucleotides. Nucleic Acids 2008; 27: 585-91.Wortmann R.L, Macdonald P.A, Hunt B. et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 2010; 32: 2386-97.Halevy S, Ghislain P.D, Mockenhaupt M. et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.Weisskopf M.G, O’Reilly E, Chen H. et al. Plasma urate and risk of Parkinson’s disease. Am J Epidemiol 2007; 166: 561-7.Kim T.S, Pae C.U, Yoon S.J. et al. Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatric Psychiatry 2006; 21: 344-8.Abraham A, Drory V.E. Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis. J Neurol 2014; 261: 1133-8.Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine 2015; 82: 141-3.Noman A, Ang D.S, Ogston S. et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010; 375: 2161-7.Bardin T, Chales G, Pascart T. et al. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine 2016; 83: 314-7.Kydd A.S, Seth R, Buchbinder R. et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014; 11: CD010457.Hira D, Chisaki Y., Noda S. et al. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 2015; 96: 90-8.Schumacher H.R Jr, Becker M.A, Wortmann R.L. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59: 1540-8.Becker M.A, Schumacher H.R.Jr, Wortmann R.L et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-61.Becker M.A, Schumacher H.R, Espinoza L.R et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.Abeles A.M. Febuxostat hypersensitivity. J Rheumatol 2012; 39: 659.Chohan S. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 2011; 38: 1957-9.Givertz M.M, Anstrom K.J, Redfield M.M. et al. Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study. Circulation 2015; 131: 1763-71.Choi H.K, Soriano L.C, Zhang Y. et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190.Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fen of ibrate: a systematic review and meta-analysis of randomized placebo controlled trials. Pharmacol Res 2015; 102: 63-70.Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol 2012; 157: 255-7.Rothenbacher D, Primatesta P, Ferreira A.et al. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 2011; 50: 973-81.Dalbeth N, Chen P., White M. et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis 2014; 73: 797-802.Yamanaka H. Gout and hyperuricemia in young people. Curr Opin Rheumatol 2011; 23: 156-60.Luk A.J, Simkin P.A. Epidemiology of Hyperuricemia and Gout. Am J Manag Care 2005; 11: 435-42.Roddy E, Choi H.K. Epidemiology of gout. Rheum Dis Clin North Am 2014; 40: 155-75.Атаханова Л.Э., Цурко В.В., Булеева И.М. и др. Подагра: от этиологии и патогенеза к диагностике и рациональной терапии. Современная ревматология. 2007; 1: 13-8.Kuo C.F., Grainge M.J, Mallen C. et al. Eligibility for and prescription of urate-lowering treatmentinpat in patients with incident gout in England. JAMA 2015; 312: 2684-6.Цурко В.В., Елисеева М.Е., Воробьев П.А. Особенности течения подагры в пожилом возрасте. Терапевт. арх. 2014; 5 (86): 50-5.Воробьев П.А., Цурко В.В., Елисеева М.Е. Подагра в гериатрической практике. Методические рекомендации. Часть I. Клин. геронтология. 2016; 3-4 (22): 3-9.Liu S.C, Xia L, Zhang J. et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS ONE 2015; 10: e0134088.Clarson L.E, Hider S.L, Belcher J. et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis 2015; 74: 642-7.Choi H.K, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007; 116: 894-900.Juraschek S.P, Kovell L.C, Miller E.R. et al. Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum 2013; 42 (6): 551-61.Кашкадаева А.В., Аверинова С.Г., Алехин А.П. и др. Диагностика факторов риска почечной недостаточности на базе концентрационно-скоростного подхода к анализу результатов комплексной реносцинтиграфии в онкологической практике. Рос. электронный журн. лучевой диагностики. 2013; 3 (2): 47-62. www.rejr.ruSayapina M.S, Averinova S.G, Zacharova T.V. et al. Complex Monitoring of Biochemical and Radionuclide Parameters in Patients with Metastatic Renal Cell Carcinoma during Immunotherapy. Int J Nephrology 2017. DOI: 10.1155/2017/8549502Саяпина М.С., Аверинова С.Г., Захарова Т.В. и др. Биохимический и радионуклидный мониторинг функции единственной почки у больных метастатическим почечно-клеточным раком на фоне иммунотерапии. Экспериментальная и клин. урология. 2017; 3: 118-25.